Oregon Attorney General Files $900 Million Lawsuit Against Insulin Manufacturers and PBMs for Price Inflation Scheme
Oregon Attorney General Dan Rayfield has initiated a legal action against major insulin manufacturers and pharmacy benefit managers (PBMs) with a $900 million lawsuit. The lawsuit alleges that the insulin manufacturers, including Novo Nordisk, Sanofi, and Eli Lilly, colluded with PBMs like Express Scripts, CVS Caremark, and Optum to artificially inflate the prices of insulin and other diabetes medications. This alleged coordination aimed to increase profits by boosting list prices and securing favorable placement on PBM formularies, followed by significant rebates and fees paid back to the PBMs.
The lawsuit, filed in Multnomah County Circuit Court, highlights the detrimental impact of the alleged scheme on Oregonians. It claims that individuals were compelled to ration medication, use expired insulin, reuse needles, or skip meals to manage blood sugar levels, jeopardizing their health and well-being. Oregon Attorney General Rayfield emphasized that the lawsuit goes beyond insulin prices, addressing the financial strain and health risks faced by families when corporations exploit their lack of alternatives.
Furthermore, the lawsuit alleges that manufacturers and PBMs deliberately excluded lower-cost insulin options from formularies, limiting access to more affordable alternatives for consumers. PBMs play a crucial role as intermediaries in the prescription drug supply chain, collaborating with health insurers and employers to oversee prescription drug benefits.
In seeking justice for affected consumers, Rayfield aims to halt the alleged scheme through a court order and secure restitution exceeding $900 million. The lawsuit underscores the importance of holding pharmaceutical companies and PBMs accountable for their actions, particularly when they impact individuals' access to essential medications and exacerbate financial and health challenges.